Arcticzymes Financial Statements From 2010 to 2025
| AZT Stock | NOK 18.22 0.38 2.04% |
Check Arcticzymes Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcticzymes Technologies' main balance sheet or income statement drivers, such as , as well as many indicators such as . Arcticzymes financial statements analysis is a perfect complement when working with Arcticzymes Technologies Valuation or Volatility modules.
Arcticzymes |
Arcticzymes Technologies ASA Company Current Valuation Analysis
Arcticzymes Technologies' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Arcticzymes Technologies Current Valuation | 3.42 B |
Most of Arcticzymes Technologies' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arcticzymes Technologies ASA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Arcticzymes Technologies ASA has a Current Valuation of 3.42 B. This is 76.21% lower than that of the Healthcare sector and 26.43% lower than that of the Biotechnology industry. The current valuation for all Norway stocks is 79.44% higher than that of the company.
Arcticzymes Technologies Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Arcticzymes Technologies's current stock value. Our valuation model uses many indicators to compare Arcticzymes Technologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arcticzymes Technologies competition to find correlations between indicators driving Arcticzymes Technologies's intrinsic value. More Info.Arcticzymes Technologies ASA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.60 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Arcticzymes Technologies ASA is roughly 1.65 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Arcticzymes Technologies' earnings, one of the primary drivers of an investment's value.About Arcticzymes Technologies Financial Statements
Arcticzymes Technologies investors utilize fundamental indicators, such as revenue or net income, to predict how Arcticzymes Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and markets recombinant enzymes derived from cold-water marine species and organisms from other relevant environments for use in molecular research, in vitro diagnostics , and therapeutics in Norway, Europe, Asia, Australia, Africa, and the Americas. ArcticZymes Technologies ASA was incorporated in 1990 and is headquartered in Troms, Norway. ARCTICZYMES TECH operates under Biotechnology classification in Norway and is traded on Oslo Stock Exchange. It employs 30 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Arcticzymes Stock
Arcticzymes Technologies financial ratios help investors to determine whether Arcticzymes Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Arcticzymes with respect to the benefits of owning Arcticzymes Technologies security.